Sign In
Buy MDWD
$14.12
+0.0200 (+0.142%)
At Close: Jul 31, 2026
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 19'th Feb 2026
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- Med
MediWound to Present at Upcoming Investor Conferences
08:00am, Tuesday, 17'th Feb 2026
MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17 , 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t
MediWound Ltd. (NASDAQ:MDWD) Given Consensus Recommendation of “Moderate Buy” by Analysts
01:41am, Sunday, 18'th Jan 2026
MediWound Ltd. (NASDAQ: MDWD - Get Free Report) has earned an average rating of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
07:00am, Monday, 12'th Jan 2026
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid ® 's Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Ltd. (MDWD) Q3 2025 Earnings Call Transcript
10:43am, Thursday, 20'th Nov 2025
MediWound Ltd. ( MDWD ) Q3 2025 Earnings Call November 20, 2025 8:30 AM EST Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executi
MediWound (MDWD) Reports Q3 Loss, Misses Revenue Estimates
09:11am, Thursday, 20'th Nov 2025
MediWound (MDWD) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $0.98 per share a year ago.
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:00am, Thursday, 20'th Nov 2025
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Commissioning Completed for Expanded NexoBrid ® Facility; Full Operational Capacity Expected by Year-End 2025
MediWound to Report Third Quarter 2025 Financial Results
07:30am, Wednesday, 05'th Nov 2025
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd.
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid®
08:00am, Monday, 03'rd Nov 2025
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
08:37am, Monday, 29'th Sep 2025
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
07:30am, Thursday, 25'th Sep 2025
MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia
MediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress
07:30am, Tuesday, 02'nd Sep 2025
MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global lea
MediWound Is A Buy Opportunity On The Dip
05:42am, Tuesday, 02'nd Sep 2025
MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the compan
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Wednesday, 20'th Aug 2025
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer,
